Skip to main content
    W

    Whitehawk Therapeutics, Inc. (WHWK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.01
    -0.05 (-1.63%)

    Market Cap: $180.57M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Whitehawk Therapeutics, Inc. (WHWK) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Whitehawk Therapeutics reported revenue of $7.14M for the fiscal year ended Dec 31, 2025, down 72.5% from the year before. That year, net income was -$20.60M with a net margin of -288.3%, operating cash flow was -$97.43M and free cash flow was -$97.98M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$21.21M.

    Revenue and Margins

    Over the 7 years to Dec 2025, revenue fell from $20.16M, a compound annual decline of 13.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$7.14M-72.5%89.4%-1601.1%-288.3%
    Dec 2024$25.98M+6.7%88.4%-259.6%-245.1%
    Dec 2023$24.35M+60.1%88.5%-295.4%-270.0%
    Dec 2022$15.22M+1258.6%91.2%-411.9%-397.7%
    Dec 2021$1.12M-92.3%100.0%-9930.1%-9829.5%
    Dec 2020$14.58MN/A100.0%-17.5%-23.9%
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$20.16MN/A100.0%-55.5%-51.6%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$7.14M$25.98M$24.35M$15.22M$1.12M$14.58M$0$20.16M$0$0
    Cost of revenue$760.00K$3.02M$2.81M$1.33M$0$0$0$0$0$0
    Gross profit$6.38M$22.96M$21.55M$13.88M$1.12M$14.58M$0$20.16M$0$0
    Research and development$90.96M$51.03M$48.93M$32.66M$19.67M$15.01M$12.82M$17.85M$12.15M$11.37M
    Operating income-$114.40M-$67.46M-$71.93M-$62.68M-$111.22M-$2.55M-$24.44M-$11.18M-$21.39M-$16.63M
    Net income-$20.60M-$63.69M-$65.77M-$60.51M-$110.09M-$3.48M-$23.27M-$10.40M-$21.40M-$16.98M
    EBITDA-$28.27MN/AN/AN/A-$109.53MN/A-$24.22M-$11.13M-$21.17M-$16.24M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$7.14M$7.24M$7.21M$6.18M$5.35M$6.33M
    Gross profit$0$0$0-$1.00K$0$0$6.38M$6.45M$6.41M$5.40M$4.70M$5.40M
    Operating income-$22.94M-$18.11M-$23.52M-$24.89M-$19.55M-$54.75M-$15.22M-$18.95M-$13.41M-$15.58M-$19.51M-$17.71M
    Net income-$21.21M-$16.64M-$22.19M-$23.25M-$17.75M-$52.62M$73.02M-$18.27M-$12.55M-$14.58M-$18.29M-$16.27M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $37.57M were 24.9% of total assets of $150.83M, against total liabilities of $14.52M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$150.83M$70.32M$132.42M$184.24M$157.91M$18.82M$39.94M$64.12M$21.03M$2.40M
    Current assets$149.01M$61.29M$124.59M$180.03M$151.27M$18.68M$39.57M$63.98M$20.90M$2.23M
    Cash and equivalents$37.57M$28.67M$62.89M$39.02M$148.99M$4.46M$38.52M$62.61M$20.26M$1.61M
    Total liabilities$14.52M$17.84M$27.23M$25.86M$21.50M$31.26M$3.40M$5.46M$3.59M$14.86M
    Short-term debtN/A$268.00K$434.00K$394.00K$131.00K$9.03M$8.35MN/AN/A$12.39M
    Long-term debtN/AN/AN/AN/AN/A$1.10MN/AN/AN/AN/A
    Shareholder equity$136.31M$52.48M$105.19M$158.38M$136.41M-$12.43M$36.54M$58.67M$17.44M-$86.22M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$173.69M$193.99M$127.23M$150.83M$167.02M$180.82M$234.00M$70.32M$85.70M$101.62M$111.07M$132.42M
    Total liabilities$10.53M$11.07M$11.06M$14.52M$9.85M$8.76M$12.27M$17.84M$16.83M$22.83M$20.61M$27.23M
    Cash and equivalents$68.97M$85.23M$34.79M$37.57M$37.93M$144.94M$227.57M$28.67M$30.54M$41.14M$53.78M$62.89M
    Shareholder equity$163.16M$182.93M$116.17M$136.31M$157.17M$172.07M$221.73M$52.48M$68.87M$78.79M$90.46M$105.19M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$97.43M-$59.55M-$59.66M-$49.64M-$22.42M-$12.70M-$23.85M-$5.81M-$18.88M-$15.72M
    Capital expenditures$552.00K$1.65M$3.97M$444.00K$46.00K$0$236.95K$37.91K$8.90K$113.30K
    Free cash flow-$97.98M-$61.20M-$63.63M-$50.08M-$22.47M-$12.70M-$24.09M-$5.85M-$18.89M-$15.83M
    Dividends paidN/AN/AN/A$0$4.41M$0N/AN/AN/AN/A
    Share repurchases$5.63M$0N/A$322.00K$9.62MN/A$0$3.50M$3.08MN/A
    Investing cash flow$11.89M$25.20M$83.21M-$132.89M$25.15M$0-$236.95K-$37.91K$41.10K-$113.30K
    Financing cash flow$94.38M$130.00K$326.00K$72.62M$141.80M$1.19M$0$48.20M$37.50M$12.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$19.67M-$14.53M-$22.21M-$17.23M-$15.38M-$52.96M-$11.86M-$15.05M-$15.69M-$9.16M-$19.65M-$9.64M
    Capital expenditures$3.00KN/A$0$0$0$1.00K$551.00K$186.00K$188.00K$541.00K$739.00K$816.00K
    Free cash flow-$19.68MN/A-$22.21M-$17.23M-$15.38M-$52.96M-$12.41M-$15.24M-$15.88M-$9.70M-$20.39M-$10.46M
    Last 12 quarters

    Frequently Asked Questions About WHWK

    What is Whitehawk Therapeutics' annual revenue?

    Whitehawk Therapeutics reported revenue of $7.14M for the fiscal year ended Dec 31, 2025.

    How fast is Whitehawk Therapeutics' revenue growing?

    Revenue was down 72.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -22.3%.

    Is Whitehawk Therapeutics profitable?

    No. Whitehawk Therapeutics reported net income of -$20.60M for the fiscal year ended Dec 31, 2025, with a net margin of -288.3%.

    How much free cash flow does WHWK generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$97.43M minus capital expenditures of $552.00K produced free cash flow of -$97.98M.

    How much debt does Whitehawk Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $37.57M.